Innovation for Good Health
Fosun Pharma USA Inc. is led by a team of highly experienced executives with strong track records from leading US and European pharmaceutical companies both in commercial operations and R&D.
104 Carnegie Center, Suite 204
Princeton, NJ 08540
(609) 250-2802
info.usa@fosunpharma.com
Customer Service & Adverse Event/ Quality Concerns: (855) 282-4882 or fosuncs@eversana.com
© 2024 Fosun Pharma USA Inc. All rights reserved. | Privacy Notice
Rong Yang is the chief executive officer of Fosun Pharma USA and the senior vice president of Fosun Pharma. He is responsible for expanding Fosun Pharma’s presence in the U.S., driving overall business and organizational growth and representing the company in front of external stakeholders.
Prior to Fosun Pharma, Rong was with Bayer Group for nearly 20 years in a variety of senior positions across United States and Europe. As Vice President he headed Bayer’s U.S. Specialty and Hematology sales and marketing team; he also served as Head of Business Insight and Analytics and was a member of Bayer’s Executive Committee in the United States; as Vice President of Strategy and Finance he oversaw Bayer pharmaceuticals Americas P&L across the U.S., Canada and Latin America with more than 5 billion USD revenue and more than 30 legal entities across the continent. Before moving to the U.S., he was Bayer Pharma’s Country Group General Manager for Czech Republic and Slovakia based in Prague, Czech Republic. Earlier in his career he took various portfolio and commercial roles in Germany and Austria. Rong has lived and worked in five different countries across three continents. Currently he also serves as Board Director of Nature Sunshine, a NASDAQ listed company.
Rong holds a Bachelor of Arts in German and in Economics from Beijing Foreign Studies University and an MBA from Harvard University.
Outside of work, Rong likes family time with his wife Vesna and daughter Zarja. He enjoys hiking, reading and watching soccer games.
Updated 10.2023
Jeremy Tatum serves as chief commercial officer and general manager (GM), Established Medicines for Fosun Pharma USA, and is on the Board of Directors for Novelstar Pharmaceuticals. He was initially hired as vice president of Commercial Operations and was later promoted to the Interim CEO and GM of Fosun Pharma USA. In his current role, he is responsible for all commercial operations, strategy, and development of the Established Medicines business unit in the U.S.
Jeremy has spent 29 years in healthcare, medical devices, and pharma (brand and generics). Jeremy’s leadership has shaped the commercial strategies and portfolios of companies like Merck, Cubist, Auromedics (a division of Aurobindo), and American Regent.
Jeremy holds a Bachelor of Arts in Business Psychology from the University of Arkansas at Little Rock and a Master of Arts in Health Services Administration-Informatics from the University of Phoenix.
Outside of work, Jeremy likes to work out, travel, and build anything from motorcycles to houses.
Updated 10.2023
Mousumi Sannigrahi is the chief commercial officer of Innovative Medicines at Fosun Pharma USA. She is responsible for building out the commercial team, setting up the operating infrastructure, and managing the collaboration with Henlius for Innovative Medicines. Mousumi is a seasoned leader whose experience spans product innovation and commercialization.
Prior to joining us, she served as the U.S. Head of CSU, Immunology at Novartis. At Novartis, Mousumi held different global and U.S. leadership roles in strategy, sales, marketing, and business. Before that, Mousumi was with LEK Consulting, responsible for commercial, pipeline, and investment strategies for pharma, biotech, and private equity firms. At Dainippon Sumitomo Pharma, she was part of successful launches including the blockbuster Latuda ®. She started her career at Schering Plough in R&D as a medicinal chemist in Infectious Diseases and Oncology. She is passionate about leading and building high-performing teams and bringing new innovations to patients.
Mousumi holds a Ph.D. in Organic Chemistry from the University of Alberta and an MBA from Duke University.
Outside of work, Mousumi enjoys the outdoors, art, and learning about new cultures.
Updated 10.2023
Dr. Vishal Patel is the Head of Business Development for Innovative Medicines at Fosun Pharma USA. He is responsible for corporate and business development initiatives including strategic partnerships, joint ventures and mergers & acquisitions (M&A).
Dr. Patel has over 15 years of business experience across healthcare investment banking, private equity, venture capital, business development and M&A. Previously, he was part of the business development team at Bayer Pharma focused on strategic partnerships and M&A. Prior to his role at Bayer Pharma, Dr. Patel was Vice President on the healthcare venture capital/growth equity team at HighCape Capital. Earlier in his career, Dr. Patel was a private equity investor at FS Investments (over $70 billion in assets under management globally) and a healthcare investment banker at Bank of America Merrill Lynch where he was involved in several IPO and M&A transactions.
Dr. Patel completed his medical and clinical training at Drexel University with a focus on managing and treating patients with dry eye, corneal disorders, glaucoma and retinal conditions/diseases. He also completed his Bachelor’s degree at Brandeis University.
Outside the office, Dr. Patel enjoys spending time with family and friends as well as traveling, attending stand-up comedy shows & sporting events and exploring the diverse restaurant scene in New York City.
Updated 6.2024
Stan Lechpammer serves as the vice president of Medical Affairs, Innovative Medicines at Fosun Pharma USA. He is responsible for the strategy and operations of Medical Affairs, executing a comprehensive pre-launch readiness plan to secure early adoption of serplulimab by U.S. oncologists. Stan also coordinates Medical Affairs activities with Henlius to support the ASTRIDE trial.
Prior to joining us, Stan was vice president, Medical Affairs at ImmunityBio, where he built their complete Medical Affairs capabilities in support of the organization’s first launch in the U.S. Stan has over 17 years of experience in the biotech industry and has served in positions of increasing responsibility in Medical Affairs and Clinical Development at Amgen / Onyx, Genzyme, EMD Serono, Jazz Pharmaceuticals, Medivation / Pfizer, and GSK. He participated in bringing to the market several novel oncology drugs, including NDA and sNDA launches to post-launch development in the US and ROW (Vectibix®, Nexavar®, Campath®, Defitelio®, Talzenna®, Xtandi®, and Zejula®).
Stan obtained his MD and Ph.D. from the University of Zagreb, School of Medicine in the EU and completed his post-doctoral fellowship in Radiation Oncology/Nuclear Medicine at Harvard Medical School and additional fellowships at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Stan is married to his wife Mirna and has two children, Laura and Eric. In his free time, he enjoys hiking, kayaking, and hearty BBQ.
Updated 4.2024
Annah Litzenberger serves as Chief Human Resources Officer (CHRO) of Fosun Pharma USA. As the CHRO, she is responsible for the People Strategy that balances employees’ needs with the company’s interests. She is a strategic partner that enables the business to achieve their goals through innovation and an entrepreneurial mindset. She and her team ensure that the company has the talent, culture and commitment necessary to meet its strategic plans for growth, and the leadership necessary to achieve its global objectives.
Prior to joining us, Annah was the vice president, head of HR at Xilio Therapeutics. Prior to that, she was GSK’s global head of talent and inclusion & diversity for Pharma R&D. She joined GSK through the acquisition of TESARO, where she was the head of HR. Before entering the biotech/pharma industry, Annah spent over 15 years at Santander Bank in a range of HR roles of increasing responsibility, most recently serving as senior vice president, head of learning and organizational development.
Annah holds a Bachelor of Science in Criminal Justice, with minors in Psychology and Political Science from Kutztown University of Pennsylvania.
Annah is married to her husband, Mike. They have 2 daughters, Olivia and Mackenzie, and pets Leroy and Charli. They are Disney fanatics and escape to the most MAGICAL place on earth each year. When not at work or Disney, Annah loves being at the gym, spending time with family and friends, and being anywhere warm and sunny!
Updated 10.2023
Aileen Wang is the chief financial officer of Fosun Pharma USA. Aileen’s responsibilities include leading the Finance team on activities such as budgeting, financial analysis, corporate controllership, day-to-day operations, process integration or improvement, capital markets, and investor relationships. Aileen also serves as a key finance business partner and drives critical business decisions.
Prior to joining Fosun Pharma USA, Aileen was the chief financial officer of Clover BioPharma (HKEx 02197), supporting the company from a series-C and clinical-stage biotech company to a publicly listed and commercial-stage company. Before that, Aileen worked in Novartis for over 10 years with five job rotations and had increasing leadership responsibilities in both the U.S. and China.
Aileen holds an MBA from Pennsylvania State University and a bachelor’s degree in Engineering from Shanghai Jiaotong University. She is an Illinois-registered certified public accountant (CPA) and a chartered financial analyst (CFA).
Outside of work, Aileen is married with two children (a boy and a girl). She is an animal lover and adopted a mixed-border collie dog. She also enjoys traveling with family.
Updated 10.2023
Dr. Lawrence Brown serves as vice president, general counsel for Fosun Pharma USA, with responsibility for all aspects of the organization’s legal affairs.
He is responsible for all legal and compliance affairs and activities for Fosun Pharma USA, including all litigation strategy and management; intellectual property prosecution, registration and enforcement; contract drafting, negotiation, compliance and review; corporate ethics, enforcement and policy; corporate governance; and compliance and enterprise risk management. Larry also serves as a key legal business partner and drives critical business decisions.
Prior to joining us, Larry was vice president and assistant general counsel, Intellectual Property (IP) – Generics at Endo Pharmaceuticals/Par Pharmaceutical (Endo/Par). He spent 15 years at Endo/Par in positions of increasing responsibility, overseeing patent litigation strategy, IP prosecution and management, licensing transactions, regulatory law, and antitrust. Prior to joining Endo/Par, Larry had been an associate attorney and patent agent at law firms in Boston and New York.
Larry holds a J.D. from Fordham University School of Law, a PhD in molecular biology from Princeton University, and a bachelor’s degree in Biochemical Sciences from Harvard University. He is admitted to the state bars of New Jersey, New York, and Massachusetts, and the bars of the U.S. Patent and Trademark Office, the Court of Appeals for the Federal Circuit, and the U.S. District Court for the District of New Jersey.
Outside of work, Larry is married with a daughter who is a college senior. He enjoys composing music, painting, photography, creative writing, reading, book collecting, and boating.
Updated 1.2024